

Index

- Abramson, John 250
 academic detailing 118–121
 accountability
 justice and 39, 55
 market-friendly systems 54, 55
 organizational ethics 238
 Actimmune 8
 administration costs 42
 adoption 158
 advance directives 232
 Advanced Cell Technologies 152
 advanced market commitments 75–76
 advertising. *See* DTC advertising; marketing
 Affymetrix 151
 agency 104, 113
 aging population 42
 AIDS 5, 52, 103, 121, 170, 187–189, 193–194
 Allegheny Health Education and Research
 Foundation 203
 American Association of Retired Persons 142
 American College of Surgeons 225
 American Council on Graduate Medical
 Education 207
 American Enterprise Institute 23
 American Medical Association 22, 113, 114, 117,
 152, 206, 225
 American Society of Bioethics and
 Humanities 156
 Amgen 10
 Angell, Marcia 21, 63, 72–73, 77, 119, 120, 250
 anti-free-riding principle 69
 anti-retroviral therapies 52
 antidepressants 11
 Aquinas, Thomas 185
 Arizona State University 151
 Arnold, Denis 10, 131
 Arrow, Kenneth 255
 Arthritis Foundation 159
 Association of the British Pharmaceutical
 Industry (ABPI) 104, 106, 114
 Astra Zeneca 151
 atomism 229–230
 Australia 171
 autonomy 104–109, 113, 148
 Avastin 176
 Aventis 4
 avian flu 173
 Avorn, Jerry 250
 AZT 121
 Bayer 9, 136
 BBC 205
 Beauchamp, Tom 7, 83–97
 Beecher, Henry 199
 Belgium 27
 Belsito, Marybeth 160
 Bernays, Edward 159
 bias
 disclosure worsening bias 162–165
 DTP marketing and 104–109
 medical journals 111
 self-serving bias 164
 bioethicists, power 155
 bioethics
 industry funding. *See* industry-funded
 bioethics
 models. *See* healthcare models
 biomedical model
 alternative paradigm 236–244
 characteristics 222–227
 complicity of bioethics 231–234
 cost crisis 230–231
 critics 234–236
 depersonalizing medicine 227–229
 ethical norms and economic structures 225–226
 fragmentation of care 229–230
 grounding in sciences 223
 health as absence of disease 224–225
 orthodoxy 231–234
 paternalism 228
 physician-centered 226, 232
 problems 227–231

- biomedical model (cont.)
 - reductionism 227
 - role of institutions 226–227
 - shift from 14, 220, 234–236
- biopsychological model 222, 234–235, 239
- biotechnology 155
- Biotechnology Trade Organization 151
- Bismarck, Otto von 27
- Bloch, Gregg 255
- Blue Cross Blue Shield 151
- Boniva 140
- Boorse, Christopher 224
- Bowen, Angela 154
- Brenkert, George 126
- bribery 115, 163–164
- Bush, George W. 24, 29, 36
- business
 - corrupting influence 15, 249–255
 - medicine as 22, 199–200, 204–205, 237
 - organizational ethics and 226–227
- Callahan, Daniel 3, 20–33
- Canada
 - drug prices 70, 190
 - healthcare expenditure 2, 32
 - healthcare system 3, 20, 26–27, 30–31, 39
 - parallel trade 71
 - private health insurance and 28–29
 - private healthcare 174
 - unit costs 42–43
- cancer 103, 176, 242
- Carnegie Foundation 14, 198, 215, 249
- Carnegie Mellon University 162–163
- cartoon 252
- Cato Institute 24
- Celebrex 9, 139, 159
- Center for Global Development (CGD) 75, 76
- Cephalon 8
- Cerezyme 176
- China 27, 256
- Cialdini, Robert 157
- Claritin 10, 136, 138–139
- Cleveland Clinic 163–164
- clinical trials
 - background justice 95–97
 - comparative trials III
 - compromised consent 94–95
 - constraining situations 89
 - developing countries and 6–7
 - disclosure 10–12
 - economically disadvantaged 83–84
 - exclusion option 87–88
 - exploitation 89–93
 - vulnerability 84–87
 - ethics committees and 153
 - payment as inducement 84, 88–93
 - risk 90–93, 94
 - types of influence 88–89
 - undue influence 89–93, 94
 - undue profits 90–93, 94
 - voluntariness 88–89
- Clinton, Bill 25, 36, 44–45, 202
- cloning 155
- co-payments 28, 29, 30
- coercion 89, 90, 158
- commodification 157–158
- comparative drug trials III
- competition
 - broken promises 35–36
 - competitive plans and access to drugs 49–50
 - control of cost increases 44–45
 - healthcare strategies 28, 29, 30
 - lowering unit prices 41–44
 - managed competition 52, 57
 - monopolies 43–44, 50
 - monopsonies 43, 44, 45, 50
 - non-innovative drugs 66–67
- compulsory licensing 5, 183
- conflicts of interest
 - See also* industry-funded bioethics
 - conflicts of interest committees 214
 - corruption of US healthcare 249–255
 - disclosure remedy 150–151, 165–166
 - non-disclosure problem 155–157
 - pervasiveness 254
 - rules 253
- consent
 - clinical trials 88–93, 94–95
 - compromised consent 94–95
 - informed consent 232
 - payment and 88–93
 - undue influence 89–93
- consultants 152
- consumer-driven health plans (CDHPs) 45–49, 56, 57
- consumers. *See* DTC advertising
- continuing medical education 117
- Contract Research Organizations (CROs) 153
- copyright 64–65
- corporatization of medicine 201–202
- corruption
 - business corrupting US healthcare 15, 249–255
 - industry-funded bioethics 161
- costs
 - administrative complexity 42
 - annual healthcare expenditure 1–2
 - broken promises 36, 41–52

- CDHPs, effect 45–49
 competition and access to drugs 49–50
 control of increases and competition
 44–45
 drugs 169
 DTC advertising and 134, 138–139
 malpractice costs 42
 marginal social costs 82
 unit prices and competition 41–44
 US cost crisis 230–231
 cox-2 inhibitors 108, 139, 159
 Czech Republic 27
- Daniels, Norman 3, 35–57, 180
 Davis, Phil 205
 De George, Richard 12–13, 169–171, 195
 deception, DTP marketing 104–109
 DeCode Genetics 152
 deductibles 28, 29, 46, 47
 democracy 23–24, 56
 demographics 42
 Denmark 27
 depersonalization of medicine 227–229
 detailing
 academic detailing 118–121
 bribery 115
 deception, bias and autonomy 104–109
 educative value 106–107
 gifts 113–116, 163–164
 impact 8, 204
 innovation v. regulation 118–121
 manipulation 112–113
 meaning 103
 practices 7, 103
 prescribing behavior and 116
 regulation 117–118
 rep techniques 8
 threat to patients 107–109, 111–112, 116
 trips 163
 vulnerability of physicians 109–112
 developing countries
 access to drugs 187–189, 193–195
 clinical trials in 6–7, 83–84
 drug market 67
 drug patents and 4–6, 69–70
 health funding 6, 36, 50
 immunization programs 53
 orphan drugs 74, 194–195
 privatizations 51, 57
 user fees 51–52, 57
 vulnerability 84–87
 diabetes 217
 diarrhoeal diseases 74
 Dickens, Charles 205
 dignity 140
- disclosure
 non-disclosure problem 155–157
 remedy against conflicts of interests 150–151,
 165–166
 worsening bias 162–165
 disease, concept 224–225
 doctors. *See* physicians
 Doha Declaration on TRIPS and Health 6, 72,
 74, 77
 Dow 152
 drug industry
 access obligations 184
 clinical trials. *See* clinical trials
 contribution 12–13, 169
 corrupting influence 251–253
 criticisms 169–171, 189–195
 DTP marketing. *See* detailing
 funding bioethics. *See* industry-funded
 bioethics
 influence 3–13, 83–84
 international shortcomings 193–195
 lobbying 190
 marketing. *See* marketing
 monopoly powers 43–44, 50
 obligations 182–189
 patents. *See* drug patents
 production obligations 182–183
 profitability 3–4, 103, 155, 191–195
 regulation v. innovation 12, 118–121
 rescue obligations 184–189
 right to health and 171–177
 social responsibility 188, 193
 ties with medical journals 11, 15, 111, 152, 156, 251
 withholding data 111
 drug patents
 See also research and development
 compulsory licensing 5, 183
 developing countries and 4–6, 67
 factual context 65–67
 free-riding and 67–71
 income inequalities and 69–70
 innovation 65
 issues 66–67
 marketing and 67
 misplaced criticism 189
 non-innovative drugs 65, 66–67, 69–71, 119
 paying for innovation 73–76
 reform 71–73
 drugs
 10/90 gap 66
 comparative trials 111
 marginal social costs 82
 Medicare and access to 49–50
 off-label uses 7, 251
 orphan drugs 74, 181–182, 183, 194–195

- drugs (cont.)
 parallel trade 71
 patents. *See* drug patents
 prescription drugs, nature 141, 179–181
 pricing
 British system 73
 criticism 190–191
 reference pricing 81
 tiered pricing 190–191
 US control 178–179
 public goods 67–71
 safety 10–11, 141
 US expenditure 65, 70–71
 very expensive drugs 176–177
 Drugs for Neglected Diseases Initiative 195
 DTC advertising
 branded ads 135
 categories 133, 135–136
 debate 131, 133–136
 educative function 133–134, 135, 142–143
 ethical legitimacy 136–144
 European ban 31
 healthcare costs and 134, 138–139
 help-seeking ads 133, 144
 information lacuna 179–181
 manipulative advertising 143
 nature of prescription drugs 141, 179–181
 non-branded 136, 144
 over-medication and 134, 135, 138–139
 patient–physician relationships 134–135, 143
 PhRMA guidelines 136–137, 145–146
 product claim ads 133, 137–143
 public safety and 141
 reminder advertising 133, 136–137
 rise 131–133
 statements of adverse effects 132, 133
 television 131, 132, 180
 United States 9–10, 131–146, 179–181
 DTP marketing. *See* detailing
 Dupont 152
 Eddy, David 238
 education
 continuing medical education 117
 US medical education 14–15, 207–209, 223–227
 Eflornithine 4
 Eli Lilly 8, 11, 160
 Elliott, Carl 11–12, 107, 150–166
 Enbrel 10, 240
 end of life care 233–234
 Engel, George 222, 227, 234–235, 236, 237, 239,
 240–241
 Erbitux 176
 errors 238
 ESSEC Business School, Paris 151
 Ethiopia 4
 European Federation of Pharmaceutical
 Industries and Associations (EFPIA) 194
 European Union 131
 Families USA 120
 fee splitting 225
 fiduciary ethos 105, 115, 226, 241
 Field, Sally 140
 Finland 106, 107
 Flexner II 15, 255–257
 Flexner Report 14–15, 199, 215, 249, 250
 Flexnerian model 200, 223–234, 243
 Ford 136
 fragmentation of care 229–230
 France 2, 27, 70, 190
 free-riding 67–71
 Friedman, Milton 23
 Fuchs, Victor 25
 Garber, Alan 181
 Gaucher disease 176
 Genentech 176
 Germany 24, 27, 44, 70, 81, 190
 gifts, drug companies to physicians 113–116,
 163–164
 GlaxoSmithKline 5, 9, 11, 136, 152
 Gorman, Michael 65
 Gustafson, James 231
 Harvard Medical School 110
 Hastings Center 151
 Hauerwas, Stanley 231
 Hayek, Friedrich von 23
 health
 definition 224–225
 holistic health concepts 239–240
 patients and communities 240–242
 public health 31, 250
 right to 12–13, 170, 171–177
 social context 240–242
 health reimbursement accounts (HRAs)
 45, 47
 health savings accounts (HSAs) 29, 36,
 44, 46
 healthcare
 costs. *See* costs
 market fallacy 33
 markets 20
 meaning 37–38
 medicine and 240
 models. *See* healthcare models
 right to 12–13, 170, 171–177
 social good 174
 strategies. *See* healthcare strategies

- healthcare models
 biomedical model 222–227
 problems 227–231
 biopsychological model 222, 230, 234–235
 business rhetoric 22, 199–200, 204–205, 237
 changing delivery conditions 200–204
 changing rhetoric 198–200
 complicity 231–234
 corporatization of medicine 201–202
 function of bioethics 233
 medical professionalism and 13–15
 objectives 13, 199–200
 interaction 203
 organization ethics 212–215, 226–227, 236–244
 organizational changes 198
 orthodoxy 231–234
 patient care and research 205–215
 shift 14, 220, 234–236
 stakeholders 208, 209–212
 systems-based model 14, 206–209, 221, 234–236
 value-based stakeholder approach 209–212
- healthcare strategies
 choice and democracy 23–24
 commercial model 21–22
 competition. *See* competition
 deductibles and co-payments 28, 29, 30
 efficiency 23
 ethical issues 20
 Europe and Canada 20, 26–27, 30–31, 32, 39
 European debate 23
 evaluation of market practices 28–30
 evaluation of practices 28–30
 for-profit v. non-profit 29
 government-dominated 20–21
 government-run 24
 ideologies 23–24, 25
 instrumentalism 23, 25
 intertwined values 24–25
 justice and 1–3, 23, 24, 36–41
 market strategies. *See* market strategies
 models 3
 national systems 26–27
 physician incentives 29
 private health insurance 28–29
 social solidarity and 49
 standards of judgment 26
 United States. *See* United States
 universal systems 20–21, 39, 40
- Helsinki Declaration 79
 Hemminki, Elina 106, 107
 Herceptin 176
 Heritage Foundation 24
- high-deductible plans 46, 47
 Hippocratic tradition 198, 205, 212, 216, 226
 holism 239–240
 Horton, Richard 251
 Hubbard, Jason 8, 103–121
 Hubbard, Tim 82
 Hugo, Victor, *Les Misérables* 185–186
 human rights
 right to health 12–13, 171–177
 right to life 172, 176
- Imber, Jonathan 233
 IMF 51
 immunization programs 53
 India 5, 27, 256
 individualism 240–242
 industry-funded bioethics
 conflicts of interests 11–12, 150, 154, 161
 consultants 152
 corruption 161, 249–255
 disclosure remedy 150–151, 165–166
 disclosure worsening bias 162–165
 effect on ethical behaviour 166
 forms 150, 151–154
 influence 151, 165
 IRBs 153
 lectures 153–154
 medical editors 11, 15, 111, 152, 156, 251
 non-disclosure problem 155–157
 public relations 158–160
 public trust and 161
 rebound effects 157–158
 social causes 154–155
 unnecessary funding 166
- influence
 coercion 89, 90, 158
 industry-funded bioethics 151, 165
 industry spending for 253
 manipulation 88–89, 90, 94
 payment and clinical research 88–93
 persuasion 88
 types 88–89
 undue influence 89–93, 94
- Ingraham, Leslie 155
 innovation
 infinite technological innovation 31–33
 paying for 73–76
 regulation v. innovation 12, 118–121
- Institutes of Medicine 207, 221, 222, 234, 235–236, 237, 238
- Institutional Review Boards (IRBs) 153–154, 232
- institutions
 biomedical model 226–227
 organizational ethics 238–239
- instrumentalism 23, 25

- insurance
 biomedical model 230
 private health insurance 28–29
 uninsurance 2, 52, 181
 US premiums 2
- intellectual property rights 4, 63–65
See also drug patents; patents
- InterMune 8
- Internet 159
- Israel 27
- Italy 27, 70, 190
- Jack, William 82
- Japan 171, 192
- Johns Hopkins School of Medicine 223
- Johnson & Johnson 11, 13
- Joint Commission for Accreditation of
 Health Care Organizations (JCAHO)
 212–213, 215
- Jonas, Hans 231
- journals. *See* medical journals
- justice
 ability to pay 40
 access to drugs 49–50, 69–70, 75
 benchmarks 40–41, 55–57
 CDHPs and 48
 clinical trials and 95–97
 free-riding on research and 68–69
 healthcare markets 1–3, 23, 24, 36–41
 lobbying and 190
 market mechanism 170
Les Misérables 185–186
 Rawls 37, 38–39
- Kaiser Family Foundation 143
- Kant, Immanuel 104, 140
- Kark, Sidney 247
- Kass, Leon 231
- Kassirer, Jerome 22, 117, 250, 254
- Key Opinion Leaders 153, 251
- Khushf, George 14, 220–244
- Kleinfield, N. R. 217
- Kleinke, J. D. 217
- Krimsky, Sheldon 156
- Kryzewski, Mike 158
- Lanjouw, Jean Olson 63, 72, 77, 82
- lectures 153–154
- Leder, Drew 231, 233
- Levitra 9, 136
- Lexchin, Joel 71
- life, right to 172, 176
- life expectancy 169
- Light, Donald 71, 75, 76
- Lipitor 8, 9
- lobbying 190
- Locke, John 64, 185
- Love, James 82
- Lunesta 137, 140
- McKenny, Gerald 231
- McKinnell, Hank 133–134
- Maitland, Ian 129, 192
- malaria 4, 74
- malpractice costs 42
- manipulation 88–89, 90, 94, 112–113, 143
- marginal social costs 82
- market fallacy 33
- market strategies
 accountability 54, 55
 broken promises 35–36, 41–52
 competition. *See* competition
 developing countries and 50
 effectiveness 170
 ethical and scientific review 52–57
 evaluation of market practices 28–30
 health costs promise 36
 healthcare models 30
 market-friendly solutions 35–36
 United States 3, 35–57
 advertising control 179–181
 drug pricing 178–179
 market failures 181–182
- marketing
 direct to consumers. *See* DTC advertising
 direct to physicians. *See* detailing
 disguised 159–160
 drug patent system and 67
 illegal marketing 7–8, 251
 regulation v. innovation 118–121
 spending 191–192
 US drug advertising control 179–181
- Martin, Mark 136
- medical education 14–15, 207–209, 223–227
- medical journals
 bias 111
 fiduciary ideal 241
 ties with industry 11, 15, 111, 152, 156, 251
- Medicare, competitive plans and 44, 49–50
- Melander, Hans 111
- Melarsoprol 4
- Menzel, Paul 6, 62–77
- Merck 5, 8, 10, 11, 108, 139, 140, 151, 152, 159, 191
- Merck Company Foundation 151
- Merctizan 5
- mergers 203
- Millennium Pharmaceuticals 151
- Mills, Ann 13, 198–216
- Les Misérables* 185–186
- monopolies 43–44, 50

- monopsonies 43, 44, 45, 50
 Monsanto 152
 moral hazard 46
 Morgagni, Giovanni Battista 243
 Morreim, Haavi 226, 237
 multiculturalism 241
 multinational companies 13, 187

 Nagel, T. 38
 National Institute for Health and Clinical
 Excellence (NICE) 181
 National Institute of Health (NIH) 119–120, 144
 Nemeroff, Charles 156
 Netherlands 27, 81
 Neurontin 8
 New York University 151
 New Zealand 27, 81, 146, 179
 Newcomer, Lee 108
 Nigeria 6
 North Florida University 151
 Novartis 5, 192

 OECD 2
 off-label use of drugs 7, 251
 Olanzapine 8
 organizational ethics
 business ethics and 226–227
 characteristics 212–215, 236–244
 health of patients and community 240–242
 healthcare broader than medicine 240
 holistic health concepts 239–240
 institutions and individuals 238–239
 norms and science 242–244
 Orłowski, James 163–164
 orphan drugs 74, 181–182, 183, 194–195
 orthodox bioethics 231–234

 Palmer, Tom 64, 65
 parallel trade 71
 Paris School 224, 243
 patents
 drugs. *See* drug patents
 economics 62–63
 monopolies 179
 moral arguments for 63–65
 paternalism 228
 Paxil 9
 Pellegrino, Edmund 22, 220–221, 235, 243
 Pennsylvania, University of 7, 151, 152
 Peppin, John 123
 persuasion 88
 Pfizer 6, 8, 9, 133, 135, 136, 137, 139, 151, 152, 158, 159
 pharmaceutical industry. *See* drug industry
 PhRMA 104, 106, 113–115, 131, 133, 136–137,
 152, 194

 physicians
 arrogance and insensitivity 239
 as agents 235
 biomedical model 226, 232, 239
 business rhetoric 199–200, 204–205
 continuing medical education 117
 corporatization of medicine 201–202
 corruption by industry 249–255
 detailing and. *See* detailing
 ethics 105
 fiduciary duties 105, 115, 226, 241
 knowledge of pharmacology 110
 patient care ethics 205–215
 patient–physician relationships 243
 DTC ads and 134–135, 142, 143
 physician incentives 29
 reaction to gifts 117, 163–164, 204
 sources of information 103–104, 118
 vulnerability to detailing 109–112
 Plato 21, 22
 pregnant women, vulnerability 86
 Prescription Project 115
 prices. *See* drugs
 prisoners 85, 86, 87–88
 private health insurance 28–29
 privatizations 51, 57
 property, Lockean theory 64
 Propulsid 11
 Provan 6
 Provigil 8
 public goods 67–71
 public health 31, 250
 public relations 158–160
 public trust 161, 253

 Ramsey, Paul 231
 RAND Health Insurance Experiment 46, 47,
 52, 56
 Rawls, John 37, 38–39
 Relafen 139
 Relman, Arnold 21
 rescue obligations 184–189
 research
 biomedical model 223–224
 IRBs and 232
 medical practice and 236
 medical research ethics 205–215
 research and development
 10/90 gap 66
 advanced market commitments 75–76
 annual expenditure 65
 British drug pricing system 73
 clinical trials. *See* clinical trials
 free-riding 67–71
 issues 66–67

- research and development (cont.)
 non-innovative drugs 65, 66–67, 69–71, 119
 paying for innovation 73–76
 public goods 67–71
 R&D-plus 76
 regulation v. innovation 118–121
 requirements 62
 small firms 75
 Third World diseases 74
 right to health 12–13, 170, 171–177
 right to life 172, 176
 risk, clinical trials 90–93, 94
 Robinson, James 201–202
 Roche 151
 Rorty, Mary 13, 198–216
- Sabin, James 39, 180
 Safer, Daniel 111
 safety of drugs 10–11, 141
 Sanofi-Aventis 151, 158
 Schering-Plough 8, 10, 136
 science
 bioethics and 234–235, 237
 Flexner model 199, 200, 223
 organizational model 242–244
- Sen, Amartya 37
 Senge, Peter 216
 Sepracor 137
 sepsis 160
 Seton Hall University 151
 SFBC International 94
 Singapore 5, 29
 Singer, Peter 185
 sleeping sickness 4
 Smith, Adam 21, 22, 32
 Smith, Richard 251
 SmithKline Beecham 139, 151, 152
 social proof principle 157
 social solidarity 49
 South Africa 29
 stakeholders 208, 209–212
 Stanford University 47, 152
 stem cell research 155
 Stoto, Michael 247
 Sun-Life 151
 supply side constraints 42, 45
 SUPPORT study 222, 233–234
 Sweden 27, 70
 Switzerland 27
 system-based ethics 14, 206–209, 221, 234–236
- Teagarden, Russell 180
 Thailand, generic drug production 5
 Thomasma, David 235, 243
 thought leaders 153, 251
- Toronto University 151, 152
 transnational companies 13, 187
 TRIPS 5, 6, 72, 74, 77
 trust, public trust 161, 253
 tuberculosis 74
- UNICEF 4
 uninsurance 2, 52, 181
 United Health Group 108
 United Kingdom
 drug prices 70, 73, 190
 DTP marketing 114
 expensive drugs and NHS 176
 healthcare expenditure 2
 healthcare system 24, 27
 NICE model 181
 United Nations, draft TNC norms 13
 United States
 Bay-Dole Act 120
 care reimbursement 202–203, 205
 clinical research
 oversight 83
 prisoners 87–88
 rules 90
 corporatization of medicine 201–202
 drug budget 65, 70–71
 drug industry
 developing countries and 170
 DTC advertising 9–10, 131–146,
 179–181
 DTP marketing 113–116
 lobbying 190
 marketing budget 7
 non-innovative drugs 66–67
 orphan drugs 181–182, 183, 194
 pricing 190–191
 profitability 3–4, 103, 191–195
 research 119–120
 safety 10–11
 health insurance 2, 52, 181
 healthcare system
 budget 1, 2, 103
 care reimbursement 202–203
 characteristics 22, 26
 Clinton plan 25, 36, 44–45, 202, 206
 corruption 15, 249–255
 cost crisis 230–231
 drug pricing control 178–179
 ethical shift 14, 220, 234–235
 ethics 205–215
 international ranking 30
 market strategies 3, 20, 29, 35–57
 private healthcare 12
 shortcomings 177
 infinite technological innovation 31–33

Index

291

- intellectual property rights 4, 77
- IRBs 153–154
- life expectancy 169
- medical education 14–15, 207–209, 223–227
- Universal Declaration of Human Rights 172
- universal systems 20–21, 39, 40
- University College, London 151
- user fees
 - anti-retroviral therapies 52
 - developing countries 51–52
 - effect 52, 57
- utilitarianism 65

- vaccines 182
- Vanderbilt University 7
- Vasella, Daniel 192
- VERICC 160
- Viagra 9, 136, 137, 140
- Vioxx 10, 11, 12, 108, 139, 159, 191
- Virginia Healthcare Ethics Network 213
- vulnerability
 - concept 86–87
 - economically disadvantaged 84–87
 - physicians to PSRs 109–112
 - vulnerable groups 85, 86

- water 172
- Wateska, Leon 163–164
- Waxman, Henry 9
- Werhane, Patricia 13, 65, 198–216
- Wikler, Daniel 15, 249–257
- Wittgenstein, Ludwig 216
- Woolhandler, S. 43
- World Bank 51
- World Health Organization 5, 11, 13
- WTO. *See* TRIPS
- Wyeth 151

- Xigris 160

- Yale School of Medicine 7

- Zaner, Richard 231
- Ziegler, Michael 106–107
- Zyprexa 8